col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt

Verlag: The Japanese Pharmacological Society

60 Ergebisse       Seite 1

 [1] 
  Original Artikel Journal Datum Titel Autoren Alle Autoren
1 [GO] Folia Pharmacologica Japonica 2025―Mai―01 Nationwide survey of practice after COVID-19 pandemic conducted in medical schools","医学部薬理学関連講座におけるCOVID-19パンデミック後の実習に関する全国実態調査の結果から Masaki Mogi, Shung Liu
2 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―07 新型コロナウイルス感染症下におけるクロマチン構造制御","Regulation of chromatin structure under COVID-19 Kinugasa Yasuha, Mara Anais Llamas-Covarrubias, Yumiko Imai
3 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―07 シングルセル情報とゲノム情報の統合解析によるCOVID-19重症化メカニズムの解明","Elucidating the mechanism of COVID-19 severity by integrative analyses of single-cell and host genetics data Edahiro Ryuya, Yuya Shirai, Yusuke Takeshima, Shuhei Sakakibara, Yuta Yamaguchi, Teruaki Murakami, et al. (+16)
4 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―07 An observational study of post COVID-19 syndrome in Japan using a medical database","メディカルデータベースを用いた日本における新型コロナウイルス感染症の後遺症研究 Kinugasa Yasuha, Mara Anais Llamas-Covarrubias, Katsuhiko Ozaki, Shinichi Higashiue, Yumiko Imai
5 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―07 COVID-19重症度予測シミュレーションと医療機械学習基盤(Medical MLOps)の構築","COVID-19 severity prediction orchestrated in medical MLOps Yachie Ayako, Yumiko Imai, Taiko Nishino, Sucheendra Kumar Palaniappan
6 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―07 新型コロナウイルスの進化","Evolution of SARS-CoV-2: Now And Then Kei Sato
7 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―07 New wave of airway 3D models: More than a proof-of-concept for pandemicpreparedness for industry Kazuhiro Ito
8 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2024―Jan―06 ACE2-from fly hearts to the heart of a pandemic","ACE2-from fly hearts to the heart of apandemic Josef Penninger
9 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Inactivation of leukocytes for prevention of severe COVID-19 Mutoh-Matsushita Akiko
10 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Depressive symptoms and cognitive dysfunction in Post Covid-19 Condition Noda Takamasa, Kaori Okabe, Yasunari Kanda, Motohiro Nishida
11 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Population analysis approaches for the spread of covid-19 pandemic in 150 countries Koshimichi Hiroki
12 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure Katsuki Wakayama, Kiichi Nakahira, Akihiko Tanaka, Yosuke Hukuda, Jing Zhao, Shin Ohta, et al. (+2)
13 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Early prediction of severe COVID-19 progression by a novel lung injury-related biomarker protein Arakawa Noriaki
14 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 The prediction of therapeutic targets and microRNA network in the coronavirus pathogenesis pathway Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, et al. (+2)
15 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Single cell multiomic analysis of PBMCs from SARS-COV-2 infected patients Mara Anais Llamas Covarrubias, Yasuha Kinugasa, Yutaka Suzuki, Yumiko Imai
16 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 ACE2-like carboxypeptidase B38-CAP suppresses severe acute lung injury induced by aspiration pneumonia and abdominal sepsis as well as SARS-CoV-2 infection Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Satoru Nirasawa, Jianbo An, Saori Takahashi, et al. (+2)
17 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Development of a SARS-CoV-2 infection model using human iPSC-derived intestinal epithelium Yamada Shigeru, Takamasa Noda, Kaori Okabe, Shota Yanagida, Motohiro Nishida, Yasunari Kanda
18 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Antiviral activity of curcumin and its analogs selected by artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells Hirotsugu Komatsu, Takeshi Tanaka, Zhengmao Ye, Ken Ikeda, Takao Matsuzaki, Tamotsu Shiroma, et al. (+3)
19 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Strategy for Development of Therapeutics for HIV/AIDS, Chronic Hepatitis B, and SARS-CoV-2/COVID-19 Hiroaki Mitsuya
20 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Dez―25 Role of histone ubiquitination in SARS-CoV2 and influenza virus infection Kinugasa Yasuha, Midori Hoshizaki, Mara Llamas Covarrubias, Yumiko Imai
21 [GO] Folia Pharmacologica Japonica 2022―Okt―31 A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs Daiki Ousaka, Masahiro Nishibori
22 [GO] Folia Pharmacologica Japonica 2022―Jun―30 Treatment of COVID-19 Kazuhiro Yatera
23 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Therapeutic effects of angiotensin converting enzyme 2 (ACE2) enzyme activity on acute lung injury in COVID-19 Tomokazu Yamaguchi, Midori Hoshizaki, Takafumi Minato, Satoru Nirasawa, Masamitsu Asaka, Mayumi Niiyama, et al. (+9)
24 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Development of Therapeutics for HIV/AIDS, CHB and COVID-19 Hiroaki Mitsuya
25 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Development of vaccines and therapeutics for COVID-19. Kiyama Ryuichi
26 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 A new approach to combat the sepsis including COVID-19 by accelerating detoxification of hemolysis-related DAMPs Daiki Ousaka, Dengli Wang, Masahiro Nishiboli
27 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Human iPSC-based models to evaluate COVID-19 drugs Yasunari Kanda
28 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 PMDA's efforts to promote medical innovation in the coronavirus pandemic Yasuhiro Fujiwara
29 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 The coronavirus-related signaling pathway networks and prediction modeling with activity plots. Shihori Tanabe, Sabina Quader, Ryuichi Ono, Horacio Cabral, Kazuhiko Aoyagi, Akihiko Hirose, et al. (+2)
30 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Eco-pharma research focusing on ACE2-mediated SARS-CoV-2 entry Kato Yuri, Yasunari Kanda, Motohiro Nishida
31 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Characteristics of SARS-CoV-2 mRNA/LNP vaccines and their official verification Hanada Kentaro
32 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 SARS-CoV-2 research using stem cell and organ-on-a-chip technologies Takayama Kazuo
33 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Establishment of SARS-CoV-2 respiratory tract infection model in CAG promoter-driven hACE2 transgenic mice Utsumi Daichi, Masamitsu Asaka, Haruhiko Kamada, Satoshi Nagata, Yutaka Nakachi, Tomokazu Yamaguchi, et al. (+3)
34 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2022―Mrz―20 Development of artificial antibody against receptor binding domain of SARS-CoV-2 spike protein. Masahiro Oike, Hirotaka Takahashi, Tatsuya Sawasaki
35 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Role of ACE2 in COVID-19 Yumiko Imai
36 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Engineered ACE2 receptor has a potential for a new therapy of COVID-19 Yumi Itoh, Hajime Enatsu, Akira Takada, Toru Okamoto
37 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Development of COVID-19 drugs using human iPS cell technology Shigeru Yamada, Yasunari Kanda
38 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Eco-pharma research aimed at developing COVID-19 therapeutic agent Yuri Kato, Kazuhiro Nishiyama, Akiyuki Nishimura, Motohiro Nishida
39 [GO] Folia Pharmacologica Japonica 2022―Feb―28 Drug screening for COVID-19 using supercomputer “Fugaku” Yasushi Okuno
40 [GO] Folia Pharmacologica Japonica 2021―Dez―31 COVID-19 drug candidate pipeline, an overview Hiroyuki Sugiyama
41 [GO] Folia Pharmacologica Japonica 2021―Dez―31 Remdesivir for COVID-19 Yasuhisa Fujita
42 [GO] Folia Pharmacologica Japonica 2021―Dez―31 Drug repositioning to combat COVID-19 using artificial intelligence system Norihisa Shindo, Hiroyoshi Toyoshiba
43 [GO] Folia Pharmacologica Japonica 2021―Dez―31 Contribution to development of remedies for COVID-19: focusing on Eritoran Kappei Tsukahara
44 [GO] Folia Pharmacologica Japonica 2021―Okt―31 Responses to the COVID-19 pandemic and its impacts on pharmacology education in the universities and colleges in Japan: nationwide emergency survey jointly conducted by the Physiological Society of Japan and the Japanese Pharmacological Society Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Satoshi Tanaka, Masabumi Minami
45 [GO] Folia Pharmacologica Japonica 2021―Apr―30 Therapeutic potential of nanocurcumin in COVID-19 Koji Teshima
46 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Construction of the multi-layer omics data generation / analysis platform that contributes to the precision medicine of COVID-19 Yumiko Imai
47 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Treatment of COVID-19 Kazuhiro Yatera
48 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Remdesivir for COVID-19 Yasuhisa Fujita
49 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 COVID-19 Drug Candidate Pipeline, An Overview Hiroyuki Sugiyama
50 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Suppression of SARS-CoV-2-induced lung injury by ACE2-like carboxypeptidase B38-CAP in COVID-19 mouse model Tomokazu Yamaguchi, Takafumi Minato, Midori Hoshizaki, Masamitsu Asaka, Satoru Nirasawa, Mayumi Niiyama, et al. (+10)
51 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Nationwide Emergency Survey Results on the Response to COVID-19 Pandemic and Its Effect on Pharmacological Education Conducted in the Department of Pharmacology in Universities and Colleges Jointly by the Physiology Society of Japan and the Japanese Pharmacological Society. Masaki Mogi, Tomoyuki Furuyashiki, Kazuhiro Takuma, Ken-ichi Otsuguro, Tomoyuki Tanaka, Masabumi Minami
52 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Eco-pharma research aimed at developing COVID-19 therapeutic agent Kato Yuri, Motohiro Nishida
53 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Drug repositioning to combat COVID-19 using artificial intelligence system Norihisa Shindo, Hiroyoshi Toyoshiba
54 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Drug Screening for COVID-19 using Supercomputer "Fugaku" Yasushi Okuno
55 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Contribution to Development of Remedies for COVID-19: Focusing on Eritoran Kappei Tsukahara
56 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2021―Mrz―20 Investigation of genetic variants in SARS-CoV-2-interacting molecules of ACE2, TMPRSS2 and TLR3/7/8 across populations Lee Ji-Won, In-Hee Lee, Sek Won Kong, Tadahiro Iimura
57 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mrz―17 Treatment to prevent the development of severe COVID-19 Yumiko Imai
58 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mrz―17 In silico approaches to drug repositioning for COVID-19 at AMED-BINDS Takatsugu Hirokawa, Sekijima Masakazu, Shigenori Tanaka, Haruki Nakamura
59 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mrz―17 Nonstructural proteins of Novel Coronavirus (SARS-CoV-2) Wataru Kamitani
60 [GO] Proceedings for Annual Meeting of The Japanese Pharmacological Society 2020―Mrz―17 The initial response of the laboratory diagnosis team to SARS-CoV-2 in Japan and the current situation Makoto Takeda
 [1] 

60 Ergebisse       Seite 1



[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec